Further analysis of the results from a recent clinical trial of the type 2 diabetes drug exenatide in people with Parkinson's has revealed encouraging signs of a positive effect on mood.
The trial will test whether drug treatment with a commonly prescribed dementia drug can improve balance and walking and help to prevent falls in people with Parkinson's.
The latest update, one year into a clinical trial happening in Australia and New Zealand, show promising results for the safety and effectiveness of NTCELL® therapy.
New research has suggested a link between taking anticholinergic medications and an increased risk of developing dementia. These drugs are old and are now rarely used for Parkinson’s.
Importance of using patent data to plan health and care services and find better treatments and introducing the new national data opt-out for England from 25 May, where patients can opt-out of having their confidential info shared with the NHS.
We are pleased to announce that a Parkinson's research project has been awarded the inaugural BenevolentAI Award. The project will use an artificial intelligence platform’s capabilities to reason, deduce and suggest entirely new treatments for Parkinson’s.
Parkinson's UK is pleased to announce a new project worth £1.2million to fund essential research towards new treatment that could both improve symptoms and slow the progression of Parkinson's.
We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.